On the evening of February 16, Bluestar Adisseo Company(600299) released the company's unaudited performance express for the whole year of 2021. In 2021, the operating revenue of Bluestar Adisseo Company(600299) increased by 8% over 2020 to RMB 12.87 billion. The net profit attributable to shareholders increased by 9% to RMB 1.47 billion.
The company said that the stable growth of performance was mainly due to the increase of liquid methionine sales by 23% and special products sales by 12%. The global sales network and balanced industrial layout enable Bluestar Adisseo Company(600299) to fully understand and grasp global business trends. Proactive product price management, agile and rapid product supply and continuous operation efficiency improvement plan successfully helped Bluestar Adisseo Company(600299) partially offset the adverse impact of the sharp rise in raw material and energy costs in 2021, especially in the fourth quarter.
Jean Marc, vice chairman and CEO of Bluestar Adisseo Company(600299) , "In 2021, we overcame many difficulties through agile market response, overcame the challenges of supply chain interruption and sharp rise in raw material and energy costs, and continued to provide support to customers. In 2021, we also took actions to further improve our sustainability performance. We invested in upgrading environmental protection equipment to reduce energy and water consumption, improve production efficiency and reduce carbon and greenhouse gases Keep it to a minimum. As one example, Nanjing liquid methionine plant started the waste heat comprehensive utilization thermoelectric project in 2021, which will further improve the energy utilization efficiency of Nanjing plant. Under the background of "carbon peak" and "carbon neutralization", Bluestar Adisseo Company(600299) is committed to actively promoting the green development of the whole industry through innovative products and services, and making its own contribution to China's realization of the "30 / 60" goal. "
In the methionine business, the substantial growth of liquid methionine sales is driven by the strong sales growth in all regions of the world, especially in Latin America, the Indian subcontinent and Europe.
Despite the challenge of shortage of raw materials and energy supply, the Burgos plant in Spain and the Nanjing plant have maintained a highly stable production and operation.
Methionine prices are rising in most regions of the world, but it is not enough to offset the increase in raw material prices.
The continuous capacity expansion project helps Bluestar Adisseo Company(600299) further enhance its leading edge in the methionine industry. The phase II project of Nanjing liquid methionine plant with an annual capacity of 180000 tons is progressing smoothly, and 6 million hours of accident free have been achieved. At present, the civil engineering of the project has been completed, and the completion rate of the construction project has exceeded 99%. The project has successfully entered the pre commissioning stage, and the trial operation is expected to be carried out in the second half of 2022 as planned. The European methionine plant debottlenecking project with an additional capacity of 30000 tons has realized full capacity production since the trial operation in September 2021.
In the vitamin business, the sales prices of vitamin A and vitamin E remained strong.
In 2021, the company's special products business revenue increased by 12% to RMB 3.16 billion compared with that in 2020, mainly due to the significant growth of 62% and 16% in China and Latin America respectively; Sales of ruminant products increased by 15%; Thanks to the synergy released by framelco's business integration and the sales volume of Xili selenium increased by 31%, the nutrition and health promotion business achieved stable growth; The global palatable products business and aquatic products business achieved sales growth of 11% and 13% respectively; The digestive performance products business benefited from the further improvement of market penetration and achieved double-digit sales growth in the fourth quarter. Bluestar Adisseo Company(600299) the newly launched enzyme product luozhenbao phyplus at the end of October 2021 will promote the business of digestive products to maintain stable growth in 2022.
The "China integration strategy" proposed by Bluestar Adisseo Company(600299) in 2020 is progressing smoothly and has achieved remarkable results. The capacity expansion project of China's special products entered the basic engineering design stage in December 2021 and is expected to be put into trial operation in 2023; The new China R & D and Innovation Center (Nanjing) will be put into operation in early 2022; Bluestar Adisseo Company(600299) precise nutrition analysis (PNE) service won the 2021 innovation award of China France team cooperation in November 2021.
Bluestar Adisseo Company(600299) kaidesu, a joint venture established in cooperation with Kellers, is steadily promoting the first large-scale production unit project of Feikang innovative protein products as planned. At present, nearly 90% of the construction works of the project have been completed, and the milestone of about 900000 man hours and zero accidents has been achieved. The project and procurement are nearly completed, and the preparation for trial operation is in progress as planned. It is expected to start sales by the end of 2022.
Looking ahead, Jean Marc said, "Although the uncertainties surrounding covid-19 virus mutation and supply chain disruption still exist in 2022, we will strive to achieve rapid business growth by providing value creating products and services. In the past few years, we have fully demonstrated our ability to deliver on our commitments and our resilience to soar in adversity. We are confident to continue to ride the wind and waves and forge ahead in 2022!"
